EyePoint (EYPT) news
Recent news
Eypoint Inc: H.C. Wainwright cuts to neutral from buy
H.C. Wainwright has revised its rating for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), downgrading from "Buy" to "Neutral" . This follows the firm’s earlier "Buy" recommendation with a $23.00 price target, based on favorable safety monitoring updates for the company’s DURAVYU treatment for wet…
AInvest Wire · Aug 18, 2026Eyepoint Inc: Citigroup cuts target price to $17 from $35
AInvest Wire · Aug 18, 2026Ocular Therapeutix shares up 12.7% premarket after rival Eyepoint's eye drug misses main goal in late-stage trial
AInvest Wire · Aug 17, 2026Eyepoint shares resume trading, sink 76% after study failure
AInvest Wire · Aug 17, 2026Eyepoint Inc shares to resume trading at 07:30 am ET
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares are set to resume trading at 07:30 am ET on August 17, 2026. The company previously implemented a 1-for-10 reverse stock split on December 8, 2020, to regain compliance with the minimum closing bid price requirement of $1.00. At that time, the…
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.